Business
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
About this update from Exicure, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nExicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.\n\nPoster presentation: “Development of Spherical Nucleic Acids Targeting SCN9A For the Treatment of Neuropathic Pain” – Poster Board Assignment Number: 54\n\nExicure will have the poster for viewing both in-person and virtually during the conference. Virtual posters will go live at the start of the conference and will be available to conference attendees for 2 weeks.\n\nExicure will add the poster to its website after the conference.\n\nAbout Exicure\n\nExicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening.\n\nFor further information, see www.exicuretx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220509005183/en/\n\nMedia:\nKaren Sharma\nMacDougall\n781-235-3060\[email protected]\n\nSource: Exicure, Inc.","length":2881,"tagName":"div"}]